Clinical and Paraclinical Characterizations, Management, and Prognosis in DPPX Antibody-Associated Encephalitis: A Systematic Review
- PMID: 39693598
- PMCID: PMC11658814
- DOI: 10.1212/NXI.0000000000200350
Clinical and Paraclinical Characterizations, Management, and Prognosis in DPPX Antibody-Associated Encephalitis: A Systematic Review
Abstract
In dipeptidyl-peptidase-like protein 6 (DPPX) antibody-associated encephalitis, DPPX antibodies from serum and CSF target the extracellular subunit of the voltage-gated potassium channel 4.2. This targeting leads to a characteristic clinical triad comprising gastrointestinal symptoms (predominantly diarrhea), cognitive-psychiatric dysfunction, and manifestations of CNS hyperexcitability, with hyperekplexia being a more specific feature. This rare disease typically presents with a subacute or chronic course and often affects middle-aged and older individuals. Patients may have a weak association with certain hematologic malignancies, particularly lymphoma and chronic lymphocytic leukemia. Brain MRI typically shows normal findings or nonspecific white matter changes. DPPX antibody-associated encephalitis responds well to immunotherapy, and most patients ultimately present with a good prognosis. However, relapses can occur. To improve our understanding of this rare but treatable autoimmune encephalitis and avoid misdiagnosis, we conduct a systematic review and summarize the current knowledge of its clinical and paraclinical features, management, and prognosis.
Conflict of interest statement
The authors report no relevant disclosures. Go to
Figures



Similar articles
-
Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels.Ann Neurol. 2013 Jan;73(1):120-8. doi: 10.1002/ana.23756. Epub 2012 Dec 7. Ann Neurol. 2013. PMID: 23225603 Free PMC article.
-
Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.Curr Neurol Neurosci Rep. 2025 Jul 1;25(1):45. doi: 10.1007/s11910-025-01432-8. Curr Neurol Neurosci Rep. 2025. PMID: 40591029 Review.
-
Case report: Ofatumumab treatment in anti-DPPX autoimmune encephalitis.Front Immunol. 2024 Jun 27;15:1320608. doi: 10.3389/fimmu.2024.1320608. eCollection 2024. Front Immunol. 2024. PMID: 39007139 Free PMC article.
-
DPPX antibody-associated encephalitis: Main syndrome and antibody effects.Neurology. 2017 Apr 4;88(14):1340-1348. doi: 10.1212/WNL.0000000000003796. Epub 2017 Mar 3. Neurology. 2017. PMID: 28258082 Free PMC article.
-
[Update of clinical management in autoimmune encephalitis-2024].Rinsho Shinkeigaku. 2025 Jun 26;65(6):409-415. doi: 10.5692/clinicalneurol.cn-002102. Epub 2025 May 24. Rinsho Shinkeigaku. 2025. PMID: 40399061 Review. Japanese.
Cited by
-
Anti-dipeptidyl-peptidase-like protein-6 (DPPX) autoimmune encephalitis associated with severe multifocal dystonia.Clin Park Relat Disord. 2025 Apr 2;12:100320. doi: 10.1016/j.prdoa.2025.100320. eCollection 2025. Clin Park Relat Disord. 2025. PMID: 40241920 Free PMC article.
-
Case Report: Treatment of delayed tremor episodes in a patient with DPPX antibody encephalitis.Front Immunol. 2025 Jul 30;16:1594823. doi: 10.3389/fimmu.2025.1594823. eCollection 2025. Front Immunol. 2025. PMID: 40808961 Free PMC article.
-
Anti-dipeptidyl-peptidase-like protein-6 antibody-associated encephalitis masquerading as weight loss and confusion: a case report.BMC Neurol. 2025 Jul 30;25(1):308. doi: 10.1186/s12883-025-04337-8. BMC Neurol. 2025. PMID: 40739495 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical